Orthomyxoviridae

Targus® Announces Availability of its UV-C LED Disinfection Light to Automatically Disinfect High-Touch Surfaces

Retrieved on: 
Thursday, June 29, 2023
DNA, Maintenance, Methicillin-resistant Staphylococcus aureus, MRSA, Light, Targus, Staphylococcus aureus, Sale, Klebsiella pneumoniae, Tablet, Disinfectant, Klebsiella, Mouse, Orthomyxoviridae, Safety, H1N1, Sewage treatment, Pneumonia, Bacteria

ANAHEIM, Calif., June 29, 2023 /PRNewswire/ -- Targus®, the number one laptop case brand in the US and Canada1 and a leader in laptop cases and mobile computing accessories, today announced that its CES® 2021 Innovation Awards Honoree2, the UV-C LED Disinfection Light, is now available for sale. This essential no-touch solution helps reduce pathogens on device surfaces by utilizing UV-C Light technology, which breaks down the DNA of microorganisms.

Key Points: 
  • This essential no-touch solution helps reduce pathogens on device surfaces by utilizing UV-C Light technology, which breaks down the DNA of microorganisms.
  • Sleek, modern, and lightweight, the Disinfection Light is designed to stand between your keyboard and monitor on the desktop to automatically disinfect the surfaces of keyboards, mice, and other items within the disinfection range3, reducing the need for manual intervention, cleaning, or touching.
  • The Targus UV-C LED Disinfection Light runs for 5 minutes, every hour, to clean the active disinfection area.
  • The UV-C LED Disinfection Light ( AWV339TT ) can be purchased in the US on Targus.com and through authorized resellers.

Pneumagen Announces Appointment of John Beadle as Non-Executive Director

Retrieved on: 
Tuesday, May 10, 2022
Molecule, COVID-19, University, London Business School, Founding, GlaxoSmithKline, Advanced Therapy Medicinal Product, RSV, Biotechnology, Imperial College London, IFV, Tumor microenvironment, Patient, Infection, ATMP, MCB, Founder, RTI International, RTI, Risk, Ministry of Education (Malaysia), MD, University of the Witwatersrand, MBA, Orthomyxoviridae, CEO, West African College of Physicians, Coronavirus, Degenerative disease, Pharmaceutical industry, Management, Vaccine, Pfizer

Douglas Thomson, CEO of Pneumagen, commented,"I am delighted that we have been able to attract someone of John's calibre to join Pneumagen's Board.

Key Points: 
  • Douglas Thomson, CEO of Pneumagen, commented,"I am delighted that we have been able to attract someone of John's calibre to join Pneumagen's Board.
  • John Beadle is a highly entrepreneurial CEO and leader with broad experience in building successful innovation driven biotechnology companies.
  • John Beadleadded, "I believe that Pneumagen can make a significant difference to the treatment of viral respiratory tract infections with its world-class science, strong IP and highly experienced management team.
  • Pneumagen was established in 2016 as a spin-out from the University of St Andrews in Scotland giving Pneumagen access to world-class scientific expertise and capabilities in viral RTI's specifically related to glycobiology.

Pneumagen Announces Appointment of John Beadle as Non-Executive Director

Retrieved on: 
Tuesday, May 10, 2022
Molecule, COVID-19, University, London Business School, Founding, GlaxoSmithKline, Advanced Therapy Medicinal Product, RSV, Biotechnology, Imperial College London, IFV, Tumor microenvironment, Patient, Infection, ATMP, MCB, Founder, RTI International, RTI, Risk, Ministry of Education (Malaysia), MD, University of the Witwatersrand, MBA, Orthomyxoviridae, CEO, West African College of Physicians, Coronavirus, Degenerative disease, Pharmaceutical industry, Management, Vaccine, Pfizer

Douglas Thomson, CEO of Pneumagen, commented,"I am delighted that we have been able to attract someone of John's calibre to join Pneumagen's Board.

Key Points: 
  • Douglas Thomson, CEO of Pneumagen, commented,"I am delighted that we have been able to attract someone of John's calibre to join Pneumagen's Board.
  • John Beadle is a highly entrepreneurial CEO and leader with broad experience in building successful innovation driven biotechnology companies.
  • John Beadleadded, "I believe that Pneumagen can make a significant difference to the treatment of viral respiratory tract infections with its world-class science, strong IP and highly experienced management team.
  • Pneumagen was established in 2016 as a spin-out from the University of St Andrews in Scotland giving Pneumagen access to world-class scientific expertise and capabilities in viral RTI's specifically related to glycobiology.

Cocrystal Pharma Presents Preclinical Data from COVID-19 Antiviral Programs and Outlines Near-Term Clinical Plans at the World Antiviral Congress 2021

Retrieved on: 
Wednesday, December 1, 2021
Patient, Private Securities Litigation Reform Act, Cros, Government, Safety, Risk, Technology, Annual report, Protease, Viral load, Norovirus, Severe acute respiratory syndrome coronavirus 2, SEC, Doctor of Philosophy, Pharmacokinetics, Vaccine, COVID-19, Cocrystal, Orthomyxoviridae, Omicron, Nasdaq, Research, GLOBE, Middle East respiratory syndrome–related coronavirus, Nobel Prize, COCP, Lead, United, FDA, Food, CMOS, Open Secrets: India's Intelligence Unveiled, Pharmaceutical industry

BOTHELL, Wash., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company, today presented favorable preclinical data from its COVID-19 programs and outlined its clinical plans to advance two antiviral compounds at the World Antiviral Congress 2021 in San Diego. The presentation, “Discovery of Oral, Broad-Spectrum SARS-CoV-2 MproInhibitors: Advancing to Clinical Development,” was delivered by Cocrystal President and co-interim CEO Sam Lee, PhD and is available here.

Key Points: 
  • Within the COVID-19 programs, he discussed in vitro and in vivo properties of Cocrystals intranasal and oral main protease (Mpro) inhibitors and its clinical development plans.
  • Our SARS-CoV-2 protease inhibitors showed broad-spectrum antiviral activity against Alpha, Beta, Delta, and Gamma variants in vitro.
  • In addition, our high resolution cocrystal structures using our proprietary platform technology further confirmed these results, said Dr. Lee.
  • The World Antiviral Congress 2021 provides a venue for discussing antiviral vaccines, immunotherapies and antiviral therapies.

Cocrystal Pharma’s SARS-CoV-2 Main Protease Inhibitors Demonstrate Pan-viral Activity against Human Common Coronaviruses, Noroviruses, Rhinoviruses, and Enteroviruses

Retrieved on: 
Monday, November 8, 2021
Protease, Orthomyxoviridae, Private Securities Litigation Reform Act, Cocrystal, Government, Nobel Prize, Work, CDC, Risk, Severe acute respiratory syndrome coronavirus 2, COVID-19, Diarrhea, Research, Annual report, Common, Human, Vomiting, Vaccine, Hospital, GLOBE, Chinese Center for Disease Control and Prevention, Virus, Infection, SEC, School, GameChanger, Center, Respiratory tract, COCP, Nasdaq, Patient, Nursing, Norovirus, Gastroenteritis, Death, Pharmaceutical industry

These protease inhibitors were discovered using the companys proprietary structure-based drug discovery technology and are currently being advanced by Cocrystal toward clinical development to combat SARS-CoV-2 and its variants.

Key Points: 
  • These protease inhibitors were discovered using the companys proprietary structure-based drug discovery technology and are currently being advanced by Cocrystal toward clinical development to combat SARS-CoV-2 and its variants.
  • Our current focus is on advancing these SARS-CoV-2 main protease inhibitors toward clinical development as a potential oral treatment for patients with COVID-19, he added.
  • We now have additional opportunities with these same protease inhibitors for future programs that target other areas of high unmet medical need.
  • Common human coronaviruses, not to be confused with SARS-CoV-2, usually cause mild to moderate upper-respiratory tract illnesses, like the common cold.

Cocrystal Pharma Submits Pre-Investigational New Drug Briefing Package to the FDA for Clinical Development Guidance of CDI-45205 for COVID-19 Treatment

Retrieved on: 
Monday, November 1, 2021
Inhalation, Protease, Research, CFO, United, Cros, Cocrystal, Vaccine, Orthomyxoviridae, Patient, Private Securities Litigation Reform Act, FDA, Food, SEC, Severe acute respiratory syndrome coronavirus 2, Government, Communication, Nobel Prize, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Toxicology, Annual report, Respiratory system, COCP, CEO, CMOS, COVID-19, IND, Drug discovery, Nasdaq, Risk, GLOBE, Mouse, Norovirus, Enzyme, Pharmaceutical industry

BOTHELL, Wash., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces the submission of a pre-Investigational New Drug (IND) briefing package to the U.S. Food and Drug Administration (FDA) for its broad-spectrum protease inhibitor CDI-45205 for the treatment of patients with COVID-19.

Key Points: 
  • The pre-IND submission is a critical step to obtain the FDAs guidance on preclinical studies, manufacturing, toxicology, and clinical development plans for CDI-45205.
  • As with all of our antiviral candidates, we are exploring multiple routes of administration including oral, inhalation, and injection, added Dr. Lee.
  • We are also advancing preclinical studies with our novel oral COVID-19 protease inhibitors developed using our proprietary structure-based drug discovery technology, and are very excited about potential multiple treatment options for COVID-19.
  • A number of drugs are being developed as COVID-19 treatments that were originally designed for other indications.

Cocrystal Pharma to Present Data from its Oral and Intranasal COVID-19 Therapeutics Programs at the World Antiviral Congress 2021

Retrieved on: 
Thursday, October 21, 2021
Orthomyxoviridae, Nasdaq, Nobel Prize, Protease, COCP, GLOBE, Cocrystal, Norovirus, CEO, COVID-19, Severe acute respiratory syndrome coronavirus 2, Pharmaceutical industry

BOTHELL, Wash., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company), a clinical-stage company discovering and developing novel antiviral therapeutics, announces that President and co-interim CEO Dr. Sam Lee will present new data from its COVID-19 programs at the World Antiviral Congress 2021 being held in San Diego.

Key Points: 
  • BOTHELL, Wash., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company), a clinical-stage company discovering and developing novel antiviral therapeutics, announces that President and co-interim CEO Dr. Sam Lee will present new data from its COVID-19 programs at the World Antiviral Congress 2021 being held in San Diego.
  • We are grateful to the conference organizers for once again selecting Cocrystal to speak at this prestigious gathering of antiviral experts, said Dr. Lee.
  • We look forward to sharing exciting new preclinical data from our novel COVID-19 oral and intranasal protease inhibitors.
  • The World Antiviral Congress 2021 provides a venue for discussing antiviral vaccines, immunotherapies and antiviral therapies.

Cocrystal Pharma to Present at the Dawson James 2021 Small Cap Growth Conference on October 21, 2021

Retrieved on: 
Thursday, October 14, 2021
CFO, Norovirus, Nobel Prize, Severe acute respiratory syndrome coronavirus 2, COVID-19, Nasdaq, Dawson, Calendar, Conference, COCP, GLOBE, Cocrystal, Orthomyxoviridae, Pharmaceutical industry, Vaccine

BOTHELL, Wash., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of coronaviruses, influenza, hepatitis C viruses and noroviruses, announces that management will present at the Dawson James 2021 Small Cap Growth Conference on Thursday, October 21, 2021 at 2:00 p.m. Eastern time (10:00 a.m. Pacific time).

Key Points: 
  • BOTHELL, Wash., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of coronaviruses, influenza, hepatitis C viruses and noroviruses, announces that management will present at the Dawson James 2021 Small Cap Growth Conference on Thursday, October 21, 2021 at 2:00 p.m. Eastern time (10:00 a.m. Pacific time).
  • We also look forward to discussing milestones with our COVID-19 antiviral programs during the presentation at this conference.
  • A webcast of the presentation will be available live and archived on the IR Calendar of the company website.
  • Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs.

Cocrystal Pharma Receives Australian Regulatory Clearance to Initiate Phase 1 Study of CC-42344 for the Treatment of Pandemic and Seasonal Influenza

Retrieved on: 
Wednesday, October 6, 2021
Nobel Prize, Clinical trial, Pharmacokinetics, Vaccine, WHO, Risk, Annual report, Private Securities Litigation Reform Act, Cocrystal, Norovirus, Death, World Health Organization, Centers for Disease Control and Prevention timeline, CDC, COCP, CMOS, Center, World, Trial of the century, Cros, Orthomyxoviridae, COVID-19, Severe acute respiratory syndrome coronavirus 2, Safety, Nasdaq, Government, SEC, GLOBE, Pharmaceutical industry

The Phase 1 randomized, double-blind, placebo-controlled study is expected to enroll 56 healthy volunteers at a single site in Australia.

Key Points: 
  • The Phase 1 randomized, double-blind, placebo-controlled study is expected to enroll 56 healthy volunteers at a single site in Australia.
  • CC-42344 binds to a highly conserved PB2 site of influenza polymerase complex and exhibits a novel mechanism of action that inhibits viral replication.
  • CC-43244 is specifically designed to be effective against pandemic and seasonal influenza A strains and emerging avian influenza viruses.
  • We are delighted to begin our first clinical study with CC-42344 as a treatment for this major global health concern.

TrippBio announces publication of data supporting the antiviral potency of TD-213 against SARS-CoV-2 in Scientific Reports

Retrieved on: 
Monday, September 13, 2021
Hyperuricemia, Nature, Probenecid, Cloxacillin, FDA, Methicillin, Orthomyxoviridae, CEO, University, Plasma, Doctor of Philosophy, Manuscript, Patient, Doctor of Pharmacy, Infection, Severe acute respiratory syndrome coronavirus 2, Pharmacokinetics, COVID-19, Ampicillin, Gout, Degenerative disease, Scientific Reports, Oxacillin, Pharmaceutical industry, Vaccine

These results are being used to design appropriate clinical trials to evaluate the efficacy of TD-213 as a treatment for mild-to-moderate COVID-19.

Key Points: 
  • These results are being used to design appropriate clinical trials to evaluate the efficacy of TD-213 as a treatment for mild-to-moderate COVID-19.
  • "These data demonstrate a very potent antiviral effect of TD-213 against SARS-CoV-2," said Ralph Tripp, PhD.
  • Probenecid is a favorable antiviral drug candidate as it is commercially available and has high plasma concentrations with a benign clinical safety profile.
  • TrippBio is founded on the scientific research of Ralph Tripp, Ph.D., Georgia Research Alliance Chair and professor at the University of Georgia.